ArticleIn silico pharmacology2025
2D-QSAR and molecular docking based virtual screening and molecular dynamic simulation of the indole based herbal molecules for the discovery of potent molecules in the treatment of Alzheimer's disease.
Article in In silico pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Exploring Indole-Based Molecules as Novel Therapeutics for Parkinson's Disease: A Comprehensive Review.Mini reviews in medicinal chemistry · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alzheimer's disease, a significant health challenge predominantly affecting the elderly, currently lacks curative treatments, with existing therapies offering only symptomatic relief. This study aimed to identify herbal indole-based molecules with therapeutic potential against Alzheimer's disease. A 2D QSAR model was developed for virtual screening, identifying five promising herbal molecules with predicted biological activity. Molecular docking studies further narrowed the candidates to three molecules-Evodiamine, Hyrtinadine A, and Lyaloside-which exhibited superior docking scores compared to the standard drug Donepezil against Crystal Structure of Recombinant Human Acetylcholinesterase (PDB Id-4ey7). Molecular dynamics simulations validated the stability of these molecules' interactions with the target receptor. These findings suggest that Evodiamine, Hyrtinadine A, and Lyaloside hold potential as leads for developing effective treatments for Alzheimer's disease. Despite the encouraging insights obtained from the molecular docking and 2D-QSAR techniques, the study is constrained by the absence of in vitro and in vivo confirmation, requiring additional experimental assessments. To determine their therapeutic potential against Alzheimer's disease, future studies should concentrate on the pharmacokinetic profiles and preclinical evaluations of the identified lead compounds. Graphical abstract: Supplementary Information: The online version contains supplementary material available at 10.1007/s40203-025-00364-y.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.